HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
Closed Posted
- Opportunity number
- RFA-AT-22-005
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.213 Research and Training in Complementary and Integrative Health
- 93.233 National Center on Sleep Disorders Research
- 93.279 Drug Use and Addiction Research Programs
- 93.307 Minority Health and Health Disparities Research
- 93.313 NIH Office of Research on Women's Health
- 93.350 National Center for Advancing Translational Sciences
- 93.361 Nursing Research
- 93.837 Cardiovascular Diseases Research
- 93.838 Lung Diseases Research
- 93.839 Blood Diseases and Resources Research
- Funding instrument
- Cooperative Agreement
- Categories
-
- Education
- Health
- Eligible applicants
-
- Tribal Organizations (Not Federally Recognized)
- City/Township Governments
- Higher Education Inst. (Public)
- Special District Governments
- For Profit Organizations
- State Governments
- Other
- Independent School Districts
- Public or Indian Housing Auth.
- 501(c)(3) Nonprofits
- Non-501(c)(3) Nonprofits
- Tribal Governments (Federally Recognized)
- Higher Education Inst. (Private)
- County Governments
- Small Businesses
- Full announcement
Opportunity details come from Grants.gov. Updated .
Synopsis
The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed. However, opioid medication use alone should not be the only intervention studied. Trials supported under this initiative may also address the impact of these approaches on related psychological and functional outcomes to support improved overall well-being and quality of life. In addition, studies that address stigma, structural health care system, and social factors that may hinder quality comprehensive pain care for patients with SCD are also of interest. Investigators are encouraged to include the collection of well-justified biological markers or psychological processes that have demonstrated that they may mediate pain outcomes. Trials should collect sufficient measures to phenotype participants such as type of pain, variability of pain, co-occurring conditions, and social determinants of health. The studies must address questions within the mission and research interests of the NIH HEAL Initiative and evaluate preventive or treatment strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, behavioral interventions, rehabilitation strategies, complementary interventions, integrated approaches, and delivery system strategies in well controlled trials in patients with SCD to manage acute and/or chronic pain.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity